TY - JOUR
T1 - Expert consensus on the management of chronic lymphocytic leukaemia in Asia
AU - Tse, Eric
AU - Kwong, Yok Lam
AU - Goh, Yeow Tee
AU - Bee, Ping Chong
AU - Ng, Soo Chin
AU - Tan, Daryl
AU - Caguioa, Priscilla
AU - Nghia, Huynh
AU - Dumagay, Teresita
AU - Norasetthada, Lalita
AU - Chuncharunee, Suporn
AU - Radhakrishnan, Vivek
AU - Bagal, Bhausaheb
AU - Atmakusuma, Tubagus Djumhana
AU - Mulansari, Nadia Ayu
N1 - Funding Information:
Eric Tse has received research support from MSD. Priscilla Caguioa has served on scientific advisory boards for Astra Zeneca, Novartis, MSD, Takeda, Otsuka, Johnson and Johnson, and has received research support from Astra Zeneca, Roche, MSD, Mylan, Celltrion, Apellis International, and MorphoSys AG. Teresita Dumagay was the Primary Investigator in the Acalabrutinib Trial sponsored by AstraZeneca and has received an honorarium for separate lectures from Astra Zeneca, Janssen Pharmaceuticals, and Novartis. Vivek Radhakrishna has received advisory fees (institutional) from Pfizer India and institutional grants and/or non-financial support from Intas Pharmaceuticals, Natco Pharmaceuticals, Roche India, BMS, Cipla Pharmaceuticals, Emcure, AstraZeneca, and Dr. Reddy’s Laboratories, outside the submitted work.
Funding Information:
The authors thank BioQuest Solutions for providing editorial assistance and publication coordination which was funded by AstraZeneca Singapore in accordance with Good Publication Practice (GPP) guidelines 2022.
Publisher Copyright:
© 2023, The Author(s).
PY - 2023
Y1 - 2023
N2 - In recent years, considerable progress has been made in the standard treatment for chronic lymphocytic leukaemia (CLL) due to the availability of new potent drugs. However, the majority of data on CLL were derived from Western populations, with limited studies and guidelines on the management of CLL from an Asian population perspective. This consensus guideline aims to understand treatment challenges and suggest appropriate management approaches for CLL in the Asian population and other countries with a similar socio-economic profile. The following recommendations are based on a consensus by experts and an extensive literature review and contribute towards uniform patient care in Asia.
AB - In recent years, considerable progress has been made in the standard treatment for chronic lymphocytic leukaemia (CLL) due to the availability of new potent drugs. However, the majority of data on CLL were derived from Western populations, with limited studies and guidelines on the management of CLL from an Asian population perspective. This consensus guideline aims to understand treatment challenges and suggest appropriate management approaches for CLL in the Asian population and other countries with a similar socio-economic profile. The following recommendations are based on a consensus by experts and an extensive literature review and contribute towards uniform patient care in Asia.
KW - Asia
KW - Bcl-2 inhibitors
KW - BTK inhibitors
KW - Chronic lymphocytic leukaemia
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85148217301&partnerID=8YFLogxK
U2 - 10.1007/s10238-023-01007-2
DO - 10.1007/s10238-023-01007-2
M3 - Letter
C2 - 36795237
AN - SCOPUS:85148217301
SN - 1591-8890
VL - 23
SP - 2895
EP - 2907
JO - Clinical and Experimental Medicine
JF - Clinical and Experimental Medicine
IS - 6
ER -